Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that diphlorethohydroxycarmalol significantly increased prostaglandin $E_2$ synthesis in HaCaT human keratinocytes by upregulating COX-1 and COX-2 expression, suggesting potential benefits from elevated $PGE_2$ production.

This letter to the editor about prostaglandins in androgenetic alopecia in men and women reports no new research findings.

This study found a negative correlation between dietary monoene levels, particularly oleic acid, and the capacity for PGE₂ synthesis in rat skin, with the most severe skin issues noted in those fed Zephyr rapeseed oil.

No genetic link between prostaglandins and hair loss found.

This study found that the distribution of mast cell prostaglandin d-synthase in the scalp spatially aligns with the pattern of androgenetic alopecia, suggesting a programmed vulnerability to hair loss.

This case report describes a rare complication of prostaglandin analogue eye drops for glaucoma, where a patient experienced extensive unwanted malar hair growth, leading to potential therapy discontinuation.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This study reports that mutations in human L-PGDS affect the entrance and exit of ligands in its binding cavity, suggesting these residues play a role in ligand interaction processes.

This study found that increased levels of PGD2 and prostacyclin and decreased levels of PGE2 and PGF2α were associated with baldness in androgenetic alopecia, suggesting potential targets for treatment.

This review discusses the roles of prostaglandins in the nervous system and their therapeutic potential for neurological diseases, noting their complex interactions with immune cells and signaling pathways.

The authors concluded that pattern hair loss is a complex condition with limited treatment efficacy and two FDA-approved drugs, finasteride and minoxidil, to slow its progression.

This case report describes a 54-year-old woman who developed hypertrichosis around a leg ulcer while using PGE1 ointment, suggesting a potential side effect of the treatment.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.

The studies reviewed found favorable treatment outcomes for hypopigmented scars using PGF2α agonists with no adverse events reported. However, the authors highlight the need for larger randomized controlled trials to better understand their effectiveness and long-term safety.

This study found that finasteride may affect Ca 2+ signalling in human sperm by interacting with the PGE 1 -binding site, but its impact on fertilization requires further investigation.

This study suggests that the expression of the DP2 receptor is higher in balding scalp cells and that its knockdown could inhibit the transition to the catagen phase in cultured human hair follicles, potentially counteracting hair growth inhibition associated with male pattern baldness.

This study reported that the PTGER2 gene is strongly expressed in cashmere goat skin and its expression tends to decrease from the anagen to telogen stages of the hair follicle cycle.

Blocking a protein called prostaglandin D2 might help treat hair loss.

This study found that a PGE2 matrix, when injected subcutaneously, increased the proportion of developing hair follicles and improved hair follicle stem cell markers in a mouse model of hair loss.

In this study, PGD2 treatment in keratinocytes increased testosterone production via reactive oxygen species, suggesting a potential role for the NRF2 pathway in androgenic alopecia treatment strategies.

This study identified that blocking the PTGDR2 receptor in human hair follicles in vitro and in mice reversed the hair growth inhibition caused by PGD2, suggesting a potential approach for treating alopecia.

This case report highlights a rare side effect of prostaglandin analogues, detailing prostaglandin-associated periorbitopathy in three glaucoma patients treated with bimatoprost and travoprost.

This review explores the therapeutic applications of bimatoprost, including its role in glaucoma treatment, hair growth stimulation, and potential effects on fat deposition, but reports no new experimental findings.

This review suggests that imbalance in prostaglandin levels may contribute to androgenetic alopecia, highlighting prostaglandins as potential biomarkers and therapeutic targets for the condition.

This study uncovered that bimatoprost, a prostaglandin analog, promotes hair growth by activating hair follicle progenitor cells through two pathways: the PTGFR-MAPK signaling axis and an unexpected IGF1R-PCAD-AKT signaling axis, suggesting new potential targets for treating hair disorders.

In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.

This study demonstrated that PGF 2α significantly stimulates hair growth in human hair follicles via a receptor-driven mechanism, with a notably stronger response in intermediate follicles than in terminal ones, suggesting potential clinical significance for conditions like alopecia.

This review by St. Denis et al. highlights that prostaglandin E2 is overexpressed in several skin cancers and suggests targeting its pathway could offer potential treatments for these malignancies.

This study found that intralesional injection of triamcinolone acetonide combined with latanoprost (a PGF2α analog) was more effective in treating localized alopecia areata, showing higher treatment response rates and greater reduction in severity scores compared to other treatments.

This study found that local PGE2 injection may prevent radiotherapy-induced hair loss by protecting hair follicle cells and promoting hair follicle self-repair.